Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That Is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery



Status:Recruiting
Healthy:No
Age Range:15 - Any
Updated:3/14/2019
Start Date:April 19, 2017
End Date:December 31, 2023

Use our guide to learn which trials are right for you!

A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma

This phase II trial studies how well trametinib works in treating patients with epithelioid
hemangioendothelioma that has spread to other places in the body, nearby tissue or lymph
nodes, or cannot be removed by surgery. Trametinib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth.

PRIMARY OBJECTIVES:

I. Estimate the objective response rate (ORR) using Response Evaluation Criteria in Solid
Tumors version 1.1 (RECIST 1.1).

SECONDARY OBJECTIVES:

I. Estimate the 6-month and median progression free survival (PFS) rates. II. Estimate the
2-year and median overall survival (OS) rates. III. Evaluate the safety of trametinib in
patients with epithelioid hemangioendothelioma.

IV. Evaluate patient-reported symptoms using National Institutes of Health Patient Reported
Outcomes Measurement Information System (NIH PROMIS) global health; pain intensity,
interference and behavior short form inventories prior to, after 4 weeks and after 6 months
(if stable or better disease) of treatment, and on evidence of disease progression.

EXPPLORATORY OBJECTIVES:

I. Compare the rates of epithelioid hemangioendothelioma progression prior to starting
trametinib to rates on treatment by central review of radiology images.

II. Evaluate the effect of trametinib on change in tumor volume and compare to RECIST 1.1
response through central imaging review.

III. Evaluate the effect of trametinib on markers of inflammation including c-reactive
protein (CRP), erythrocyte sedimentation rate (ESR) and plasma connective tissue growth
factor (CTGF).

OUTLINE:

Patients receive trametinib orally (PO) once daily (QD) on days 1-28. Courses repeat every 28
days for up to 52 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 6 months.

Inclusion Criteria:

- Patients must have measurable disease, defined as at least one lesion that can be
accurately measured in at least one dimension (longest diameter to be recorded for
non-nodal lesions and short axis for nodal lesions) as >= 20 mm (>= 2 cm) with
conventional techniques or as >= 10 mm (>= 1 cm) with spiral computed tomography (CT)
scan, magnetic resonance imaging (MRI), or calipers by clinical exam; baseline imaging
must be obtained within 30 days of day 1 of study

- Patients must have histologically confirmed epithelioid hemangioendothelioma which is
metastatic or locally advanced (unresectable), and tumor tissue (paraffin-embedded
tissue block or tumor tissue on unstained glass slides) available for fusion
fluorescence in situ hybridization (FISH) analysis at Cleveland Clinic; patient tumor
tissue stored in pathology archives may be used for fusion FISH; a new biopsy is not
mandatory

- Patients must have evidence of disease progression per RECIST 1.1 prior to enrollment
or have evidence of cancer-related pain requiring symptom management with narcotic
analgesics

- Patients previously untreated or treated with drug therapy for epithelioid
hemangioendothelioma (EHE) are eligible; there is no limit on the number of prior
regimens used to be eligible

- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)

- Life expectancy of greater than 6 months

- Able to swallow orally-administered medication and does not have any clinically
significant gastrointestinal abnormalities that may alter absorption such as
malabsorption syndrome or major resection of the stomach or small bowel

- All prior treatment-related toxicities must be Common Terminology Criteria for Adverse
Events version 5.0 (CTCAE v5) grade =< 1 (except alopecia) at the time of enrollment

- Absolute neutrophil count (ANC) >= 1 x 10^9/L (within 2 weeks of patient registration
[for blood results] and 30 days of registration for left ventricular ejection fraction
[LVEF] assessment)

- Hemoglobin >= 9 g/dL, patients may receive transfusion to meet criterion (within 2
weeks of patient registration [for blood results] and 30 days of registration for LVEF
assessment)

- Platelets >= 75 x 10^9/L (within 2 weeks of patient registration [for blood results]
and 30 days of registration for LVEF assessment)

- Albumin >= 2.5 g/dL (within 2 weeks of patient registration [for blood results] and 30
days of registration for LVEF assessment)

- Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (within 2 weeks of
patient registration [for blood results] and 30 days of registration for LVEF
assessment); NOTE: patients with elevated bilirubin secondary to Gilbert's disease are
eligible to participate in the study

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x
institutional ULN (within 2 weeks of patient registration [for blood results] and 30
days of registration for LVEF assessment)

- Serum creatinine =< 1.5 mg/dL OR calculated creatinine clearance (Cockcroft-Gault
formula) >= 50 mL/min OR 24-hour urine creatinine clearance >= 50 mL/min (within 2
weeks of patient registration [for blood results] and 30 days of registration for LVEF
assessment)

- LVEF >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or
multigated acquisition scan (MUGA) (within 2 weeks of patient registration [for blood
results] and 30 days of registration for LVEF assessment)

- Women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry, during
the study participation, and for four months after the last dose of the drug; women of
child-bearing potential must have a negative serum pregnancy test within 14 days prior
to enrollment and agree to use effective contraception throughout the treatment period
and for 4 months after the last dose of study treatment; should a woman become
pregnant or suspect she is pregnant while she or her partner is participating in this
study, she should inform her treating physician immediately

- Human immunodeficiency virus (HIV)-patients positive for human immunodeficiency virus
(HIV) are NOT excluded from this study, however HIV-positive patients must meet the
following criteria:

- A stable regimen of highly active anti-retroviral therapy (HAART)

- No requirement for concurrent antibiotics or antifungal agents for the prevention
of opportunistic infections

- A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard
polymerase chain reaction (PCR)-based test

Exclusion Criteria:

- Prior systemic therapy with a MEK inhibitor

- History of another malignancy

- Exception: patients who have been disease-free for 3 years or patients with a
history of completely resected non-melanoma skin cancer and/or patients with
indolent secondary malignancies, are eligible; consult the Cancer Therapy
Evaluation Program (CTEP) medical monitor if unsure whether second malignancies
meet the requirements specified above

- History of interstitial lung disease or pneumonitis requiring supplemental oxygen or
treatment with oral or intravenously administered corticosteroids

- Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity (e.g.
doxorubicin), biologic therapy, or immunotherapy within 21 days prior to enrollment
and/or daily or weekly chemotherapy (e.g. sunitinib, sorafenib and pazopanib) without
the potential for delayed toxicity within 14 days prior to enrollment

- Use of other investigational drugs within 28 days (or five half-lives, whichever is
shorter; with a minimum of 14 days from the last dose) preceding the first dose of
trametinib and during the study

- Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression

- Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
chemically related to trametinib, or excipients or to dimethyl sulfoxide (DMSO)

- Current use of a prohibited medication; the following medications or non-drug
therapies are prohibited:

- Other anti-cancer therapy while on study treatment; (note: megestrol [Megace] if
used as an appetite stimulant is allowed)

- Concurrent treatment with bisphosphonates is permitted; however, treatment must
be initiated prior to the first dose of study therapy; prophylactic use of
bisphosphonates in patients without bone disease is not permitted, except for the
treatment of osteoporosis

- The concurrent use of all herbal supplements is prohibited during the study
(including, but not limited to, St. John's wort, kava, ephedra [ma huang], ginkgo
biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng)

- History or current evidence/risk of retinal vein occlusion (RVO)

- History or evidence of cardiovascular risk including any of the following:

- A QT interval corrected for heart rate using the Bazett's formula QTcB >= 480
msec

- History or evidence of current clinically significant uncontrolled arrhythmias
(exception: patients with controlled atrial fibrillation for > 30 days prior to
randomization are eligible)

- History of acute coronary syndromes (including myocardial infarction and unstable
angina), coronary angioplasty, or stenting within 6 months prior to randomization

- History or evidence of current >= class II congestive heart failure as defined by
the New York Heart Association (NYHA) functional classification system

- Treatment-refractory hypertension defined as a blood pressure of systolic >140
mmHg and/or diastolic > 90 mmHg which cannot be controlled by anti-hypertensive
therapy

- Patients with intra-cardiac defibrillators

- Known cardiac metastases

- Known hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with
chronic or cleared HBV and HCV infection are eligible)

- Any serious and/or unstable pre-existing medical disorder (aside from malignancy
exception above), psychiatric disorder, or other conditions that could interfere with
subject's safety, obtaining informed consent or compliance to the study procedures

- The study drug must not be administered to pregnant women or nursing mothers; women of
childbearing potential should be advised to avoid pregnancy and use effective methods
of contraception; men with a female partner of childbearing potential must have either
had a prior vasectomy or agree to use effective contraception; if a female patient or
a female partner of a patient becomes pregnant while the patient receives trametinib,
the potential hazard to the fetus should be explained to the patient and partner (as
applicable)

- Inability to comply with protocol-required procedures
We found this trial at
33
sites
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Ciara M. Kelly
Phone: 212-639-7592
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
75 Francis street
Boston, Massachusetts 02115
(617) 732-5500
Principal Investigator: Edwin Choy
Phone: 888-823-5923
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
?
mi
from
Boston, MA
Click here to add this to my saved trials
330 Brookline Ave
Boston, Massachusetts 02215
617-667-7000
Principal Investigator: Edwin Choy
Phone: 617-667-9925
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
?
mi
from
Boston, MA
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: Scott M. Schuetze
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
720-848-0000
Principal Investigator: Victor M. Villalobos
Phone: 720-848-0650
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Christian F. Meyer
Phone: 410-955-8804
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
2500 Bellevue Medical Center Drive
Bellevue, Nebraska 68123
Principal Investigator: Nicole A. Shonka
Phone: 402-559-6941
?
mi
from
Bellevue, NE
Click here to add this to my saved trials
55 Fruit St
Boston, Massachusetts 02114
(617) 724-4000
Principal Investigator: Edwin Choy
Phone: 877-726-5130
Massachusetts General Hospital Cancer Center An integral part of one of the world
?
mi
from
Boston, MA
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Edwin Choy
Phone: 877-442-3324
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Bronx, New York 10461
Principal Investigator: Joseph A. Sparano
Phone: 718-379-6866
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Bronx, New York 10461
Principal Investigator: Joseph A. Sparano
Phone: 718-904-2730
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Bronx, New York 10467
Principal Investigator: Joseph A. Sparano
Phone: 718-379-6866
?
mi
from
Bronx, NY
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Principal Investigator: Mark Agulnik
Phone: 312-695-1301
?
mi
from
Chicago, IL
Click here to add this to my saved trials
2049 E 100th St
Cleveland, Ohio 44106
(216) 444-2200
Principal Investigator: Dale R. Shepard
Phone: 866-223-8100
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Gabriel R. Tinoco Suarez
Phone: 800-293-5066
?
mi
from
Columbus, OH
Click here to add this to my saved trials
10 Barnes West Drive
Creve Coeur, Missouri 63141
Principal Investigator: Brian A. Van Tine
Phone: 800-600-3606
?
mi
from
Creve Coeur, MO
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Principal Investigator: James L. Abbruzzese
Phone: 888-275-3853
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
Fairway, Kansas 66205
Principal Investigator: Benjamin C. Powers
Phone: 913-945-7552
?
mi
from
Fairway, KS
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Vinod Ravi
Phone: 877-312-3961
?
mi
from
Houston, TX
Click here to add this to my saved trials
Nashville, Tennessee 37232
Principal Investigator: Elizabeth J. Davis
Phone: 800-811-8480
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New Haven, Connecticut 06510
Principal Investigator: Hari A. Deshpande
Phone: 203-785-5702
?
mi
from
New Haven, CT
Click here to add this to my saved trials
New Haven, Connecticut 6520
(203) 432-4771
Principal Investigator: Hari A. Deshpande
Phone: 203-785-5702
Yale University Yale's roots can be traced back to the 1640s, when colonial clergymen led...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
New York, New York 10032
Principal Investigator: Gary K. Schwartz
Phone: 212-305-6361
?
mi
from
New York, NY
Click here to add this to my saved trials
111 North 175th Street
Omaha, Nebraska 68118
Principal Investigator: Nicole A. Shonka
Phone: 402-559-5600
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Emile St
Omaha, Nebraska 68198
(402) 559-4000
Principal Investigator: Nicole A. Shonka
Phone: 402-559-6941
Univ of Nebraska Med Ctr A vital enterprise in the nation’s heartland, the University of...
?
mi
from
Omaha, NE
Click here to add this to my saved trials
875 Blake Wilbur Drive
Palo Alto, California 94304
Principal Investigator: Kristen N. Ganjoo
Phone: 650-498-7061
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19111
Principal Investigator: Margaret von Mehren
Phone: 215-728-4790
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phoenix, Arizona
Principal Investigator: Mahesh Seetharam
Phone: 855-776-0015
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15232
Principal Investigator: Melissa A. Burgess
Phone: 412-647-8073
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Mahesh Seetharam
Phone: 855-776-0015
?
mi
from
Rochester, MN
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: Brian A. Van Tine
Phone: 800-600-3606
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
2000 Circle of Hope Dr
Salt Lake City, Utah 84112
(801) 585-0303
Principal Investigator: Anna Chalmers
Phone: 888-424-2100
Huntsman Cancer Institute at University of Utah Huntsman Cancer Institute (HCI) is part of the...
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
13400 E. Shea Blvd.
Scottsdale, Arizona 85259
480-301-8000
Principal Investigator: Mahesh Seetharam
Phone: 855-776-0015
Mayo Clinic Arizona Mayo Clinic in Arizona provides medical care for thousands of people from...
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials